|
| 37712350 | Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data. | Am J Hypertens | 2024 |
| 36565195 | Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network. | J Am Heart Assoc | 2023 |
| 37546792 | Use of Electronic Health Records to Characterize Patients with Uncontrolled Hypertension in Two Large Health System Networks. | medRxiv | 2023 |
| 37158063 | Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline-Based Chemotherapy. | J Am Heart Assoc | 2023 |
| 37205447 | Characteristics and Predictors of Apparent Treatment Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data. | medRxiv | 2023 |
| 37137641 | Disruption in Blood Pressure Control With the COVID-19 Pandemic: The PCORnet Blood Pressure Control Laboratory. | Mayo Clin Proc | 2023 |
| 37270276 | In Reply: Probability of Reduced Follow-up Health Care Visits for Controlled Hypertensive Patients. | Mayo Clin Proc | 2023 |
| 36889492 | New Drugs Approved in 2022. | Am J Med | 2023 |
| 36883471 | Seasonal variation in blood pressure control across US health systems. | J Hypertens | 2023 |
| 36695297 | Improvement in Blood Pressure Control in Safety Net Clinics Receiving 2 Versions of a Scalable Quality Improvement Intervention: BP MAP A Pragmatic Cluster Randomized Trial. | J Am Heart Assoc | 2023 |
| 36734419 | Medication Adherence-Still the Holy Grail. | J Am Heart Assoc | 2023 |
| 35235820 | New Drugs Approved in 2021. | Am J Med | 2022 |
| 35660539 | Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. | Contemp Clin Trials | 2022 |
| 35812313 | Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis. | Front Physiol | 2022 |
| 36144188 | Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients. | Metabolites | 2022 |
| 35969408 | Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial. | JAMA Intern Med | 2022 |
| 36271676 | Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients. | Clin Transl Sci | 2022 |
| 35959094 | Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease. | Am Heart J Plus | 2022 |
| 35886043 | Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. | Genes (Basel) | 2022 |
| 35252907 | Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. | Am Heart J Plus | 2022 |
| 35130051 | Acetaminophen-Induced Hypertension: Where Have All the "Safe" Analgesics Gone? | Circulation | 2022 |
| 35152405 | The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. | Clin Pharmacol Ther | 2022 |
| 35207649 | Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program. | J Pers Med | 2022 |
| 33278335 | Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans. | Clin Transl Sci | 2021 |
| 33736707 | Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. | Cardiooncology | 2021 |
| 33891615 | Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. | PLoS One | 2021 |
| 33748830 | Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. | Eur Heart J | 2021 |
| 33745898 | Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. | Am Heart J | 2021 |
| 33914047 | Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial. | JAMA Netw Open | 2021 |
| 34612048 | Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory. | J Am Heart Assoc | 2021 |
| 34564461 | Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. | Metabolites | 2021 |
| 33939997 | New Drugs Approved in 2020. | Am J Med | 2021 |
| 34348841 | Potential of Minocycline for Treatment of Resistant Hypertension. | Am J Cardiol | 2021 |
| 34071920 | Multi-Institutional Implementation of Clinical Decision Support for <i>APOL1, NAT2,</i> and <i>YEATS4</i> Genotyping in Antihypertensive Management. | J Pers Med | 2021 |
| 34231218 | Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. | Clin Pharmacol Ther | 2021 |
| 33434556 | Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. | Am J Med | 2021 |
| 33142006 | Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing. | Clin Transl Sci | 2021 |
| 31403360 | Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST). | J Womens Health (Larchmt) | 2020 |
| 33817619 | Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events - An analysis from INVESTâ¿¿. | Int J Cardiol Hypertens | 2020 |
| 31840441 | Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. | ESC Heart Fail | 2020 |
| 31891170 | Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. | Am J Hypertens | 2020 |
| 32008437 | Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification. | Hypertension | 2020 |
| 32008359 | Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension. | Circ Cardiovasc Qual Outcomes | 2020 |
| 31853537 | Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. | Am J Hypertens | 2020 |
| 33067866 | Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. | CPT Pharmacometrics Syst Pharmacol | 2020 |
| 32654539 | Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. | Circulation | 2020 |
| 32927458 | Genotype-Guided Hydralazine Therapy. | Am J Nephrol | 2020 |
| 32844549 | Optimizing identification of resistant hypertension: Computable phenotype development and validation. | Pharmacoepidemiol Drug Saf | 2020 |
| 32951360 | Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease. | J Clin Hypertens (Greenwich) | 2020 |
| 32145207 | New Drugs Approved in 2019. | Am J Med | 2020 |